Jim Simons
SPRY icon

Jim Simons’s ARS Pharmaceuticals SPRY Stock Holding History

Jim Simons’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-15,800
Closed -$229K – 3896
2024
Q3 		$229K Sell
15,800
-108,300
-87% -$1.29M ﹤0.01% 3078
2024
Q2 		$1.06M Buy
124,100
+111,500
+885% +$989K ﹤0.01% 2291
2024
Q1 		$129K Sell
12,600
-39,400
-76% -$294K ﹤0.01% 3323
2023
Q4 		$285K Sell
52,000
-85,700
-62% -$375K ﹤0.01% 3011
2023
Q3 		$521K Sell
137,700
-166,600
-55% -$1.09M ﹤0.01% 2693
2023
Q2 		$2.04M Sell
304,300
-26,300
-8% -$176K ﹤0.01% 1987
2023
Q1 		$2.15M Buy
330,600
+19,600
+6% +$151K ﹤0.01% 1986
2022
Q4 		$2.65M Sell
311,000
-3,400
-1% -$22.1K ﹤0.01% 1908
2022
Q3 		$1.66M Sell
314,400
-234,899
-43% -$1.16M ﹤0.01% 2144
2022
Q2 		$2.33M Sell
549,299
-121,243
-18% -$423K ﹤0.01% 2079
2022
Q1 		$2.35M Buy
670,542
+302,542
+82% +$1.32M ﹤0.01% 2120
2021
Q4 		$2.45M Buy
368,000
+251,400
+216% +$2.04M ﹤0.01% 1982
2021
Q3 		$1.16M Buy
+116,600
New +$2.88M ﹤0.01% 2466

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Jim Simons's SPRY Position: Q4 2024 in Review

Jim Simons sold out of ARS Pharmaceuticals (SPRY) in Q4 2024, closing a stake of 15,800 shares — an estimated $229K sold.

Jim Simons first reported a position in SPRY in Q3 2021 and held it in 13 quarters. The position peaked at $2.65M in Q4 2022. 165 funds tracked by Wall St. Rank hold SPRY as of Q4 2024.

  • Jim Simons reported no remaining ARS Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Jim Simons sold 15,800 ARS Pharmaceuticals shares in Q4 2024, an estimated $229K.
  • Jim Simons first reported a position in ARS Pharmaceuticals in Q3 2021 and held it in 13 quarters.
  • Jim Simons's ARS Pharmaceuticals position peaked at $2.65M in Q4 2022.
  • 165 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q4 2024.

Based on Renaissance Technologies's 13F filing for Q4 2024, filed 13 Feb 2025.